A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders, NORSE THREE
Sponsor: Outlook Therapeutics, Inc.
This PHASE3 trial investigates Age-related Macular Degeneration and BRVO - Branch Retinal Vein Occlusion and is currently completed. Outlook Therapeutics, Inc. leads this study, which shows 11 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Apr 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Apr 2022 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
May 2021 — Dec 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Outlook Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .